Skip to content
Menu

Cardiol Therapeutics Inc. CRDL

Full chart Compare
Set alert

Price alert · CRDL

All alert types
0.88 USD -0.07 (-7.09%)

Regular-session close

0.93 +0.05 +5.36%

After hours · Nov 19, 5:31 PM ET

0.87 Day range 0.9528
0.87 52-week range 2.34
YTD
-7.47%
1 year
-11.46%

 

No chart data for this range yet.
Market cap
112.71M
EPS (ttm)
-0.23
Shares out
81.60M
Forward P/E
-4.03
YTD return
-7.47%
1-year return
-11.46%
50-day average
1.70
200-day average
1.95
Enterprise value
103.33M
Volume
937.09K
Avg volume
1.21M
Open
0.9528
Previous close
0.9501
Day's range
0.87 – 0.9528
52-week range
0.87 – 2.34
Beta
0.70
Analysts
Buy
Price target
8.70 (+885.5%)

Key statistics

Price / book
2.89
Free cash flow
-11.63M
Total cash
24.02M
Total debt
164.27K
Return on equity
-108.43%
Short % of float
1.06%

Fundamental scorecard

4 of 25 checks passed on CRDL’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
CRDL Revenue — quarterly 0
CRDL Net income — quarterly -13.32M
CRDL EPS — quarterly -0.11

Earnings

CRDL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 2024-0.10-0.13-0.03-30.00%
Aug 12, 2024Jun 1, 2024-0.10———
Aug 12, 2024Jun 1, 2024-0.10-0.07+0.03+30.00%
May 14, 2024Mar 1, 2024-0.06———
May 14, 2024Mar 1, 2024-0.06-0.10-0.04-66.67%
Apr 1, 2024Dec 1, 20230.00-0.09——

Upgrades / downgrades

CRDL analyst upgrades and downgrades
DateFirmActionFromTo
Dec 18, 2024HC Wainwright & Co.reitBuyBuy
Nov 20, 2024HC Wainwright & Co.reitBuyBuy
Oct 24, 2024HC Wainwright & Co.reitBuyBuy
Jun 26, 2024Roth MKMinit—Buy
Jun 14, 2024HC Wainwright & Co.reitBuyBuy
Jun 7, 2024HC Wainwright & Co.reitBuyBuy

About Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Canada

News

Your note

Sign in to keep a note on CRDL — it syncs with the Stock Master app.

Institution ownership

CRDL institution ownership
Holder% heldSharesValueReported
Tejara Capital Ltd2.17%1,771,2702.21MSep 29, 2024
AdvisorShares Investments, LLC1.43%1,170,8691.46MSep 29, 2024
MMCAP International, Inc. SPC0.97%795,625994.53KSep 29, 2024
Lion Street Advisors, LLC0.33%273,281341.60KSep 29, 2024
Foundations Investment Advisors, Llc0.20%161,950202.44KSep 29, 2024
MGO One Seven, LLC0.12%100,000125.00KSep 29, 2024

Fund ownership

CRDL fund ownership
Holder% heldSharesValueReported
AdvisorShares Trust-AdvisorShares Pure Cannabis ETF1.28%1,047,2491.31MOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.06%52,43565.54KOct 30, 2024